Intrauterine and intramuscular administration of interferon was tested for effectiveness in extending luteal lifespan in cattle. Intrauterine infusion of 1 mg of recombinant bovine interferon-alphai1, twice daily, to lactating dairy cows from The three interferon-treated groups had longer interestrous intervals and functional luteal lifespans than the control group. Interestrous intervals were 22.0 ±
INTRODUCTION
The establishment of pregnancy in domestic ruminants requires embryonic signals to prevent luteolysis of the corpus luteum (CL) and secure continued progesterone secretion from the ovary. In cattle, one of the signals is produced around d 15 to 17 of gestation because embryo removal after d 15 and intrauterine infusion of embryonic homogenates or secretory products from this period extend CL function (3, 13, 16, 17) . The molecule responsible for this action has been identified as a complex of proteins called bovine trophoblast protein-1 (bTP-I) (2, 7, 9) . Infusion of bTP-1 into the uterine lumen of cyclic cows extends CL lifespan by inhibiting endometrial prostaglandin F2c t (PGF2~ release in vivo (11, 26) and inhibiting PGF2a secretion in vitro (10, 26) .
Recent studies have demonstrated that both bTP-1 and its ovine equivalent, oTP-1, have a high degree of sequence homology with interferon of the a class (5, 14, 15) . In particular, bTP-1 has a 70% predicted amino acid sequence identity with bovine interferon-tx class II (15) . Both bTP-I (8) and oTP-1 (19) possess antiviral activity. In addition, binding of radiolabelled human interferon-~ to membrane receptors from uteri of cyclic ewes can be inhibited by purified oTP-1 (24) . Salamonsen et al. (21) have shown that PGF2ct and PGE2 secretion by cultured ovine endometrial cells can be inhibited by both oTP-1 and human interferonIn a previous study (18) , we showed that intrauterine infusion of recombinant bovine interferon-txi1, type 1 (IFN) into cyclic cows from d 15.5 to 21 after estrus delayed luteolysis. This raises the possibility that interferon treatment might be a means of decreasing embryonic mortality by supplementing bTP-1 secretion of retarded or small conceptuses with exogenous interferon. For this to be practical, delivery routes more accessible and less damaging to embryos than intrauterine infusion must be found. Accordingly, the objective of the present experiment was to test whether systemic as well as intrauterine administration would extend CL iifespan.
MATERIALS AND METHODS

Preparation of Interferon
Recombinant bovine IFN (4) was supplied as a formulated lyophilized substance. In addition, a lyophilized placebo without IFN was utilized. Both of these materials were prepared by CIBA-GEIGY, Basel, Switzerland. The stock preparation of IFN had a specific antiviral activity of 1.4 x 107 units/mg protein determined by viral plaque inhibition of vesicular stomatitis virus grown on Madin-Darby bovine kidney (MDBK) cells (12) .
For intrauterine infusions, a vial containing 125 mg of lyophilized IFN was reconstituted with 12.5 ml of a filter-sterilized solution (.45-l.tm filter) of 5 mg/ml protease-free bovine serum albumin, fraction V (BSA) (Boehringer Mannheim, Indianz._polis, IN). The control vial containing the placebo formulation was also reconstituted in 12.5 ml of a sterile solution of 15 mg/ml BSA. Thus, these two solutions contained a final protein concentration of 15 mg/ml (10 mg/ml IFN and 5 mg/ml BSA for IFN infusions; 15 mg/ml BSA for control infusions), infusion solutions were loaded into .25 ml AI straws (IMV, Minneapolis, MN). For each straw, 100 p.l of the respective solution were aspirated into the middle of the straw. This bolus was bracketed between air bubbles that, in turn, were bracketed between 50 ktl of phosphate-buffered saline (10 mM NaPO4, pH 7.4, containing 154 mM NaCI, 100 1U/ml penicillin, and 100 lag/ml streptomycin). Straws were plugged and kept at 4°C until used (within less than 8 d).
For intramuscular administration, sterile water was added to a vial containing 125 mg IFN to produce a final concentration of 10 mg/ml (Experiment 2) or 2.5 mg/ml (Experiment 3). The placebo solution alone (Experiment 2) or a solution of BSA dissolved in the placebo solution to a final concentration of 2.5 mg/ml (Experiment 3) was used as control injections.
Administration of Interferon
Experiment 1. Fifteen lactating dairy cows maintained in an outdoor Lot were palpated rectally, and those possessing a functional CL were injected with 25 mg of Lutalyse ® (Upjohn Co., Kalamazoo, MI) to regress corpora lutea. Cows were checked twice daily for estrus. The first 10 cows (6 Holstein and 4 Jersey) exhibiting estrus were assigned randomly to receive control (1.5 mg of BSA/infusion; 5 cows) or IFN solutions (1.0 mg of IFN with .5 mg of BSA/infusion; 5 cows). The control and IFN solutions were introduced in utero, twice daily (0600 h and 1800 h) from d 14 (morning) through d 21 (evening) postestrus (day of estrus = d 0). The infusion technique was used as described previously (16) except that no epidural anesthesia was given.
Experiment 2. A pool of 25 dairy Simmental
heifers, 18 to 20 mo of age and weighing 350 to 420 kg, were synchronized using a prostaglandin analogue (Estrumate®; Coopers Animal Health). The first 10 heifers showing signs of estrus were selected for the study. These animals were housed in an indoor pen and fed corn silage and hay. Animals were randomly assigned to receive IFN or the placebo solution. IFN (20 mg in 2 ml) was administered intramuscularly twice daily from d 15 to 19 after estrus at 0800 and 1600 h. Control animals received an equivalent volume of placebo solution.
Experiment 3. Fifty Holstein heifers 11 to 15
mo of age, 230 to 343 kg in weight, and kept in four different outdoor pens, were rectally palpated, and those possessing a functional CL injected with 18.5 mg of Lutalyse ®. Estrous behavior was checked three times daily (0700, 0100, and 1900 h) and those detected in estrus (n = 23) were assigned randomly within pens to one of four doses of IFN (0, 2,5, 5.0, and 10.0 mg/injection). Animals receiving no IFN were given a control injection of 4 ml of BSA (2.5 mg/ml) dissolved in placebo solution. Injections were given intramuscularly twice daily (0700, 1900 h) from d 14 to 21 of the estrous cycle. The experiment was performed on two different occasions, using different heifers to obtain the necessary numbers of animals per group (n = 6, 5, 5, and 7 for 0, 2.5, 5.0, and 10.0 mg, respectively). Therefore, the statistical analysis included effects of period.
Detection of Estrus and Blood Sampling
In Experiments 1 and 3 (Florida), animals were observed twice daily (0700 and 1900 h) for estrus starting on d 13 of the estrous cycle. Detection of estrus was facilitated by the use of estrus detectors (KaMar, Steamboat Springs, CO) in Experiment 1. In both experiments, blood samples were collected from the coccygeal vein in a vacutainer tube (Becton Dickinson and Company, Rutherford, N J) once daily (between 0600 and 9030 h) beginning on d 14 of the estrous cycle and continuing until detection of estrus. Blood was allowed to clot at room temperature for 2 to 3 h and stored an additional 2 to 6 h at 4°C. The serum was harvested by centrifugation for 10 min at 500 x g and was then frozen and maintained at -20°C until concentration of progesterone was determined.
In Experiment 2 (Switzerland), estrous behavior was observed for at least 5 min at 0700, 1200, 1600, and 1900 h, starting on d 15 of the estrous cycle. Blood samples were taken daily (0730 h) by jugular venipuncture from d 15 to 26 after estrus into heparinized tubes. Samples collected on d 20 and 21 were inadvertently lost. Plasma was harvested by centrifugation at 2000 x g for 10 min at 40C and then frozen and maintained at -20°C until concentration of progesterone was determined. Personnel involved in administering injections, estrus detection, and progesterone assays were unaware of the treatment administered.
Progesterone Determination
For Experiment 1 and 3, concentrations of progesterone in serum were measured in duplicate, using 100-or 200-ktl of samples, in a radioimmunoassay as described by Knickerbocker and coworkers (16) . The intraassay and interassay coefficients of variation for four assays were 7.0 and 9.0%, respectively. Sensitivity of the assay was 31.2 pg/tube. In Experiment 2, progesterone concentrations in plasma were measured using a commercial enzyme linked immunosorbent assay kit from Cambridge Veterinary Sciences (Cambridge, UK). Detection limit of the assay was .5 ng/ml (intraassay CV = 10%).
Interferon Assay
Plasma IFN titers were assessed by a plaqueinhibition antiviral assay (12) . Results were expressed as the reciprocal of the dilution of plasma causing a 50% reduction in vesicular stomatitis virus inhibition of MDBK cell growth.
Statistical Analysis
Data analyzed were interestrous intervals and duration of functional luteal lifespan (the interval between the 1st d of estrus and the day when serum progesterone concentration first fell below 1 ng/ml). For Experiments 1 and 2, data were analyzed by one-tailed Student's t test. For Experiment 3, data were analyzed by the General Linear Models procedure of SAS (22) . The model considered effects of period, pen, treatment, period x pen, period x treatment, and pen x treatment. Since very little variation (F value <1) was associated with pen, period x pen, period x treatment, and pen x treatment, these effects were subsequently removed from the model. Differences in treatment means were evaluated by orthogonal contrasts (0 versus 2. tion of functional luteal lifespan) or normal (<24 d for interestrous intervals and <23 d duration for functional luteal tifespan). Effect of treatment on these distributions was tested by a weighted least squares analysis using the CATMOD procedure of SAS (22) . The analysis evaluated treatment effects using orthogonal contrasts as described for least square analysis of variance. Concentrations of progesterone in serum at times preceding CL regression (i.e., from d 14 to 18) were also compared between the two treatment groups to determine whether IFN affected progesterone before luteolysis. Progesterone concentration, during these 5 d did not differ (P>.10) between treatments. The least squares means of progesterone for cows receiving a control solution in utero were 7.00, 6.97, 6.89, 7.52, and 7.74 ng/ml at d 14 to 18, respectively; whereas the IFN-treated cows had least squares means of 7. Concentrations of serum progesterone preceding luteolysis (i.e., from d 14 to 18) did not differ (P>.10) between the four treatment groups. The least squares means of progesterone for heifers receiving no IFN were 8 
RESULTS
Effects of Intrauterine Infusion o1 Interferon on Interestrous Interval and Corpus Luteum Lifespan
PharmacokineUcs of Interferon Administration
Blood samples in Experiment 2 were evaluated for antiviral activity. Each day, blood was obtained prior to administration of 20 mg IFN intramuscularly and antiviral activity in peripheral blood was elevated from d 16 to 19 (mean titer = 3 to 3.5 log dilutions; Figure 2 ).
DISCUSSION
Local or systemic administration of interferon-alphall can prolong functional lifespan of the CL and length of the estrous cycle. Intra-uterine infusion of IFN prolonged the interestrous interval to an average of 30.4 d, an extension similar to results for in utero infusions of proteins from conceptus-conditioned culture medium from d 15.5 through 21 after estrus (16) . Cows receiving an intrauterine infusion of BSA also had slightly extended interestrous intervals, possibly due to uterine irritation (23, 27) . Systemic administration of IFN by an intramuscular route can also prolong interestrous interval and the functional lifespan of the CL. Administration of IFN via intramuscular injection extended estrous cycle length by an average of 2 to 4 d. It thus appears that IFN can be given to cattle to regulate luteal function through easily accessible systemic routes that do not involve the cumbersome techniques of intrauterine administration.
As in our previous study (18) , a few animals receiving IFN returned to estrus as rapidly as animals in the control groups. The reason for this is unclear. Inadequate dosage is not a plausible explanation because this phenomenon appeared in all doses in Experiment 3. Interferon may act in part through different mechanisms than bTP-1 since in vitro culture of endometrial explants from d 17 cyclic cows with bTP-1 reduced PGF production, whereas culture with IFN did not decrease PGF2et secretion but did increase secretion of prostaglandin E2 (26) . Perhaps the mechanisms that are engaged to extend CL lifespan are more affected by IFN in some animals than in others.
In cattle, early embryonic mortality represents about a 30% decrease in the overall pregnancy rate in normal cows before d 35 to 42 (1). The period from d 16 to 21 of gestation may be critical for embryonic survival as the conceptus must be present to prevent luteolysis (3, 13, 17) by secreting bTP-1 (10, 26) . A d-16 embryo measuring at least 25 mm can secrete detectable amounts of bTP-1, and secretion increases with conceptus development (6) . An optimal bTP-1 concentration may not be reached when the embryo is retarded or in asynchrony with the endometrium. Embryonic secretion of bTP-1 was reduced in embryos that are heat-stressed in vitro (20) , and such a condition in vivo would decrease embryonic survival. Thus, the application of exogenous bTP-1 or a closely related molecule such as recom-binant bovine interferon-cql may be beneficial for improving the survival of embryos secreting too little bTP-1 at the critical period for maintenance of the CL. The hypothesis that maintaining CL function pharmacologically during this critical period can be used to increase fertility is supported by data of Thatcher et al. (25) , who administered human chorionic gonadotropin at d 15 of gestation to artificially maintain CL function; subsequent fertility rate was improved by approximately 7%. Therefore, systemic administration of IFN also has the potential of increasing fertility through its actions on blocking luteolysis.
